Upload Avatar (500 x 500)
Ling Qi Liu
llqfly@163.com
English, Chinese
Hubei
Wuhan University
Medical School
  • 1997.09-2002.06 Bachelor of Clinical Medicine from Wuhan University
  • 2004.09-2010.06 PhD in Urology from Peking University
  • 2007.09-2009.10 Joint PhD training at University of Pittsburgh Medical Center, USA
  • 2010.07-2012.12 Resident Physician, Urology Department, Renmin Hospital, Wuhan University
  • 2013.01-2017.11 Attending Physician, Urology Department, Renmin Hospital, Wuhan University
  • 2017.12-present Associate Chief Physician, Urology Department, Renmin Hospital, Wuhan University
  • 2020 Hubei Province Science and Technology Progress Second Prize for 'Establishment and Technical Innovation of Flexible Ureteroscopy'
Urinary system tumors
Central regulation of male erectile function
  • MicroRNA-30a-3p functions as a tumor suppressor in renal cell carcinoma by targeting WNT2, Liu L, Chen L, Wu T, Qian H, Yang S, 2019
  • Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN, Liu L, Li Y, Liu S, Duan Q, Chen L, Wu T, Qian H, Yang S, Xin D, 2017
  • MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3, Liu L, Liu S, Duan Q, Chen L, Wu T, Qian H, Yang S, Xin D, He Z, Guo Y, 2017
  • Rapamycin prevents drug seeking via disrupting reconsolidation of reward memory in rats, Liu J, Liu L (co-first author), Wen Q, Zheng C, Gao Y, Peng S, Tan Y, Li Y, 2014
  • ELL is an HIF-1 partner that regulates and responds to hypoxia response, Liu L, Ai J, Xiao W, Liu J, Wang Y, Xin D, He Z, Guo Y, Wang Z, 2010
Urology Cancer Prostate Erectile Dysfunction Clinical Research Surgery Oncology Tumor Suppression Medical Training Public Health

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.